CMS Budapest advised US medical technology company Becton Dickinson on its new plant opened at the Tatabánya industrial park, west of Budapest, following a HUF 6bn investment. The 10,500 square-meter plant will make immunology and cellular biology research reagents used for manufacturing medical products and it will reach full capacity in 2018, when it will make 8,000 different products.
Congratulations to the team led by Senior Associate András Klupács and Real Estate Partner Gábor Czike.
